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ABSTRACT: Amyotrophic lateral sclerosis (ALS)
is an adult-onset neurodegenerative disorder character-
ized by selective loss of motor neurons (MNs). Twenty
percent of familial ALS cases are associated with muta-
tions in Cu2+/Zn2+ superoxide dismutase (SOD1). To
specifically understand the cellular mechanisms under-
lying mutant SOD1 toxicity, we have established an
in vitro model of ALS using rat primary MN cultures
transfected with an adenoviral vector encoding a mu-
tant SOD1, G93A-SOD1. Transfected cells undergo
axonal degeneration and alterations in biochemical
responses characteristic of cell death such as activation
of caspase-3. Vascular endothelial growth factor
(VEGF) is an angiogenic and neuroprotective growth
factor that can increase axonal outgrowth, block neuro-
nal apoptosis, and promote neurogenesis. Decreased
VEGF gene expression in mice results in a phenotype
similar to that seen in patients with ALS, thus linking
loss of VEGF to the pathogenesis of MN degeneration.
Decreased neurotrophic signals prior to and during dis-
ease progression may increase MN susceptibility to mu-
tant SOD1-induced toxicity. In this study, we demon-
strate a decrease in VEGF and VEGFR2 levels in the
spinal cord of G93A-SOD1 ALS mice. Furthermore, in
isolated MN cultures, VEGF alleviates the effects of
G93A-SOD1 toxicity and neuroprotection involves
phosphatidylinositol 3-kinase/protein kinase B (PI3K/
Akt) signaling. Overall, these studies validate the use-
fulness of VEGF as a potential therapeutic factor for
the treatment of ALS and give valuable insight into the
responsible signaling pathways and mechanisms
involved. ' 2009 Wiley Periodicals, Inc. Develop Neurobiol 69: 871–
884, 2009
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is an adult-
onset neurodegenerative disorder characterized by
progressive degeneration of upper and lower motor
neurons (MNs) resulting in weakness, paralysis, and
subsequent death. It has an incidence of *3–5
cases per 100,000 in the United States and consists
of both sporadic and familial forms, which are clin-
ically and pathologically indistinguishable. Familial
ALS accounts for *10% of all cases, one fifth of
which are associated with mutations in the Cu2+/
Zn2+ superoxide dismutase (SOD1) gene, with
G93A-SOD1 being the best characterized mutation
(Rosen et al., 1993). Mutations in SOD1 result in a
toxic gain of unknown function (Valentine et al.,
2005).
Vascular endothelial growth factor (VEGF), first
characterized as an angiogenic factor, is known to
have neurotrophic effects in the nervous system.
VEGF can increase axonal outgrowth (Sondell et al.,
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2000; Rosenstein et al., 2003), block neuronal apo-
ptosis (Matsuzaki et al., 2001; Li et al., 2003; Sun
et al., 2003), and promote neurogenesis (Jin et al.,
2002; Zhu et al., 2003). Within the nervous system,
there are five different isoforms of VEGF (also called
VEGF-A). The most commonly studied isoform of
VEGF is VEGF165; however, the full biological
array of VEGF isoforms may offer increased efficacy
(Carmeliet, 2003; Whitlock et al., 2004; Amano
et al., 2005). VEGF receptor-2 (VEGFR2) stimula-
tion leads to the activation of multiple signaling path-
ways including the phosphatidylinositol 3-kinase/pro-
tein kinase B (PI3K/Akt) and p44/42 mitogen-acti-
vated protein kinase (p44/42 MAPK) pathways
(Matsuzaki et al., 2001).
VEGF was first linked to ALS pathogenesis in
2001 by Oosthuyse et al. (2001). In the study, mice
lacking the hypoxia response element in the VEGF
promoter developed adult-onset muscle weakness
and neurodegeneration identical to that of ALS.
Further studies by the same group later identified
two VEGF haplotypes associated with increased
risk for developing ALS when VEGF alleles from
600 individuals with ALS and 1000 controls were
sequenced (Lambrechts et al., 2003). Since that
time, numerous studies have validated the link
between VEGF and ALS and reports have begun to
examine VEGF as a potential therapy for ALS. In
spinal cord cultures, VEGF treatment protects
against glutamate-induced MN death (Tolosa et al.,
2008). Retrograde delivery of VEGF165 to MNs by
gene therapy increases survival of G93A-SOD1
transgenic mice (Azzouz et al., 2004), and the
G93A-SOD1 transgenic rat model has also shown
evidence of increased survival in response to treat-
ment with intracerebroventricular delivery of
VEGF165 (Storkebaum et al., 2005).
While in vitro and in vivo studies have examined
the neuroprotective potential of VEGF, the mecha-
nisms of VEGF neuroprotection against mutant
SOD1 toxicity have not been established. This
study utilizes primary MN cultures transfected with
G93A-SOD1 to evaluate the effects of VEGF on
mutant SOD1 toxicity. G93A-SOD1 transfection of
primary MNs results in biochemical and morpho-
logical defects representative of MN degeneration
in ALS. We demonstrate that VEGF attenuates
G93A-SOD1-induced caspase-3 cleavage and DNA
fragmentation, which is mediated by activation of
PI3K/Akt signaling via VEGFR2. This study pro-
poses that VEGF activation of PI3K/Akt signaling
constitutes a conserved mechanism that can inter-




All animals used for these studies were housed in a patho-
gen-free environment and cared for following the Univer-
sity of Michigan Committee on the Care and Use of Ani-
mals guidelines. Animal care standards described in the
National Institute of Health Guide for Care and Use of Lab-
oratory Animals are adhered to ensure limited discomfort
and distress.
Isolation of Mouse Spinal Cords
End-stage G93A-SOD1 transgenic mice and age-matched
controls were euthanized at 120 days of age. Whole spinal
cords were collected and fresh tissue was frozen for RNA
extraction or mounted in Optimal Cutting Temperature
compound (Tissue-Tek, Sakura, Tokyo, Japan) prior to sec-
tioning. Embedded spinal cords were mounted, and 18-lm
sections were cut using a Leica CM 1850 cryostat onto
glass slides.
Primary Motor Neuron Culture
All culture reagents were obtained from Sigma (St Louis,
MO) unless otherwise noted. The primary MN treatment
media includes Neurobasal Medium (Gibco BRL, Invitro-
gen, Carlsbad, CA) with 2.5 mg/mL albumin, 2.5 lg/mL
catalase, 2.5 lg/mL SOD, 0.01 mg/mL transferrin, 15 lg/
mL galactose, 6.3 ng/mL progesterone, 16 lg/mL putres-
cine, 4 ng/mL selenium, 3 ng/mL ß-estradiol, 4 ng/mL
hydrocortisone, and 13 penicillin/streptomycin/neomycin
(Gibco BRL). For initial plating, 13 B-27 additives (Gibco
BRL) and 2 lM L-glutamine are also included. Growth
media contains all the components of the culture media
plus 13 B-27 additives.
Primary MNs were isolated according to our previ-
ously published protocol (Vincent et al., 2004). Briefly,
spinal cords from E15 Sprague–Dawley rat embryos were
collected, perineural membranes were removed, and the
tissue was chopped into 2- to 3-mm pieces. Cells were
dissociated by incubating the tissue in 0.5% trypsin/
EDTA for 10 min at 378C followed by trituration with a
serum-coated glass pipette for 1 min. The resulting cell
suspension was layered on a 5.4% Optiprep solution in
Leibowitz’s L-15 media (Gibco BRL) and centrifuged for
15 min at 2000g. The MNs were collected from the top
layer, washed in fresh L-15 media, and resuspended in
culture media. MN density was adjusted to between 2 3
104 and 2 3 106 MNs/mL, and 50 lL of the suspension
was applied to poly-L-lysine-coated glass coverslips in a
24-well plate or 1 mL of the suspension was applied to
poly-L-lysine-coated six-well plates. After 24 h, the MNs
on coverslips were fed with 250 lL growth media, and
the MNs in six-well plates were fed with 2 mL growth
media.
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MN Treatment
All MNs spent 3 days in culture prior to treatment.
Three adenoviruses, Ad5CMV humanSOD1-G93Amutant
(AdmSOD), AdCMV humanSOD1 wildtype (AdwtSOD1)
and control Ad5CMVeGFP (AdGFP), were purchased from
the Gene Transfer Vector Core at the University of Iowa
(Iowa City, IA). Viral transfection of primary MNs was per-
formed as previously described (Vincent et al., 2004).
Briefly, virus [0–1000 plaque-forming units (pfu) per MN]
was added after 2 days in culture and MNs were incubated
for 24 h prior to harvesting cell lysates or fixing for immu-
nostaining or terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL) labeling. For all VEGF experi-
ments, MNs were changed to treatment media 4 h prior to
addition of VEGF165 (Sigma). LY294002, U0126, and
SU1498 inhibitors (Calbiochem, La Jolla, CA) were added
1 h prior to VEGF at a concentration of 20 lM.
Immunostaining
Immunostaining was carried out by standard protocols as
previously described (Kim et al., 1997). Briefly, for spinal
cords, sections were permeabilized with 0.1% Triton/PBS
and then blocked in 5% normal goat serum/0.1% Triton/
PBS. VEGFR1, VEGFR2, and VEGFR3 primary antibodies
(Cell Signaling, Danvers, MA) were incubated overnight.
Sections were then incubated in Alexafluor-594-conjugated
secondary antibody (Molecular Probes, Invitrogen, Carls-
bad, CA) followed by mounting in ProLong Gold (Molecu-
lar Probes, Invitrogen). Images were collected using an
Olympus BX-51 microscope. For cultured primary MNs,
cells were grown and treated on glass coverslips followed
by fixation in 4% PFA for 5 min. Immunostaining was per-
formed as described above for spinal cord sections. Primary
antibodies used include phospho-VEGFR2-Y951 (Cell Sig-
naling), phospho-VEGFR2-Y1175 (Cell Signaling),
VEGFR2 (Cell Signaling), and ChAT (Calbiochem).
RNA Isolation and PCR
Total RNA was isolated from G93A-SOD1 transgenic and
age-matched control mouse spinal cords using the Qiagen
(Valencia, CA) RNeasy kit according to the manufacturer’s
instructions. cDNA was obtained by reverse transcription
using random primers followed by PCR using Promega
(Madison, WI) PCR MasterMix and the appropriate primer
pairs for VEGF family ligands, VEGFRs and actin. For-
ward and reverse primers were obtained from Integrated

















GCTTGCTGATCCACATCT-30. Results of at least four in-
dependent experiments were analyzed by densitometry
using Quantity One 1-D Analysis software (BioRad Labora-
tories) and normalized to actin.
Western Blotting
Western blotting was performed as previously described
(Vincent et al., 2004). MN lysates were prepared by scrap-
ing cells in RIPA buffer (20 mM Tris, pH 7.4), 150 mM
NaCl, 1 mM EDTA, 0.1% SDS, 1 mM Na deoxycholate,
1% Triton X-100, 0.1 trypsin units/lL aprotinin, 10 mg/mL
leupeptin, and 50 mg/mL PMSF. Equal amounts of protein
were loaded in each lane of a polyacrylamide gel, with gel
percentages (either 7.5 or 12.5%) dependent on the size of
the protein of interest. Nitrocellulose membranes were
incubated with primary antibody overnight at 48C and incu-
bated with appropriate horseradish peroxidase-conjugated
secondary antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA) for 1 h at room temperature. Primary antibodies
used are from Cell Signaling unless otherwise indicated:
phospho-p44/42 (Thr202/Tyr204) MAPK; phospho-Akt
(Ser473); cleaved caspase-3 (Asp175); GAPDH (Chem-
icon, Temecula, CA); antihuman SOD1 (Medical and Bio-
logical Laboratories, Nagoya, Japan); GFP. Antibody bind-
ing was developed with LumiGLO Reagent and Peroxide
(Cell Signaling) and exposed to Kodak BioMax XAR film
(Sigma). Each experimental paradigm was tested on three
separate occasions using different cultures or tissue sam-
ples. Membranes were reprobed for GAPDH to confirm
equal protein loading, and densitometry results were nor-
malized to GAPDH.
TUNEL
MNs were grown and treated on glass coverslips followed
by fixation in 4% PFA for 5 min. TUNEL was used to
detect DNA fragmentation as an indication of apoptotic
death. MN plating densities were equal between treatment
conditions and were adjusted to 50 MNs/mm2. TUNEL
analysis included blinded counting of at least 10 representa-
tive fields per condition in at least three independent experi-
ments per our published protocol for an average total of
*300 MNs per condition (Russell et al., 2002; Sullivan
et al., 2007). Samples were labeled with digoxygenin-dUTP
and then stained with horseradish peroxidase-conjugated
anti-digoxygenin antibody using the ApopTag Plus In Situ
Apoptosis Peroxidase Detection Kit (Chemicon). Alterna-
tively, for detection of fluorescent TUNEL signal, MNs
were grown and treated in 96-well culture plates. After fixa-
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tion, TUNEL processing was carried out as described above
with a Fluorecein-labeled conjugate using the ApopTag
Plus In Situ Apoptosis Fluorescein Detection Kit (Chem-
icon). Fluorescent signal was detected and recorded using a
Fluoroskan Ascent FC microplate reader (Labsystems, Hel-
sinki, Finland) (Vincent et al., 2007).
Statistical Analysis
Results are representative of at least three independent
experiments. Statistical significance was determined
using one-way ANOVA followed by Tukey’s multiple
comparison test to compare individual data points using
Prism software version 3.0 (GraphPad Software, La
Jolla, CA).
RESULTS
VEGF and VEGFRs in the Spinal Cord
To confirm the potential of VEGF to affect MNs in
ALS, MNs from G93A-SOD1 and wildtype mice
were first analyzed for the expression of VEGFRs.
Spinal cord tissue collected from endstage G93A-
SOD1 transgenic mice at 120 days of age [Fig.
1(B,D,F)] and age-matched control mice [Fig.
1(A,C,E)] was immunostained for VEGFR1,
VEGFR2, and VEGFR3. VEGFR expression is evi-
dent in ventral horn MNs in control mice and is also
evident in G93A-SOD1 transgenic mice, despite the
decreased number of MNs present. To quantify the
relative levels of VEGF family ligands and VEGFR
expression, total RNA was isolated from spinal cords
and analyzed by PCR [Fig. 1(G)]. Equal levels of
total RNA from spinal cords of transgenic and control
mice were confirmed by PCR for actin (data not
shown). There is *50% reduction in the levels of
both VEGF-A and VEGFR2 in G93A-SOD1 trans-
genic mouse spinal cords compared to control spinal
cords following quantification by densitometry. PCR
results also confirm that expression of other VEGF
family ligands and VEGFRs did not demonstrate a
compensatory upregulation to the decreased levels of
VEGF-A and VEGFR2. These data indicate a
decrease in VEGF and VEGFR2 levels in G93A-
SOD1 transgenic mice and confirm the expression of
VEGFRs on ventral horn MNs in ALS mice.
VEGF Signaling
Immunostaining of MNs isolated from E15 rat spinal
cord confirms expression of VEGFR2 in cultured
primary MNs, as indicated by ChAT co-staining to
identify MNs [Fig. 2(A–C)]. Exogenous addition of
VEGF promotes phosphorylation of VEGFR2 at
Y951 and Y1175 [Fig. 2(D–G)]. These data demon-
strate that VEGFR2 is expressed and capable of
VEGF-induced phosphorylation and activation in our
model system.
VEGF activates multiple signaling pathways in
MNs. To determine which pathways are activated
by VEGF in primary MNs, we treated cultures
with VEGF (0–500 ng/mL) for 30 min. Dose-
dependent phosphorylation of Akt and p44/42
MAPK was observed that reached maximal activa-
tion at a concentration of 250 ng/mL VEGF, while
no alterations in JNK or p38 MAPK signaling
were detected (data not shown). The temporal acti-
vation of PI3K/Akt and p44/42 MAPK signaling
was also examined. Addition of VEGF (250 ng/
mL) resulted in sustained phosphorylation of Akt
after 5 min, which persisted for at least 60 min,
while p44/42 MAPK phosphorylation peaked at 15
min [Fig. 3(A)]. Activation of both PI3K/Akt and
p44/42 MAPK signaling is prevented by inhibition
of VEGFR2 using SU1498 [20 lM; Fig. 3(B)].
The pathway-specific inhibitors LY294002 and
U0126 prevent VEGF-induced phosphorylation of
Akt and p44/42 MAPK, respectively [Fig. 3(B)].
G93A-SOD1 Effects on Primary MN
Expression of G93A-SOD1 in primary MNs results
in biochemical and morphological characteristics
resembling ALS. Transfection with AdmSOD (0–
1000 pfu/MN) promotes expression of the mutant
protein and a corresponding cleavage of caspase-3
[Fig. 4(A)], indicative of apoptotic cell death, while
transfection with AdGFP does not promote cas-
pase-3 cleavage, eliminating any toxic effects due
to viral titer alone [Fig. 4(B)]. Activation of apo-
ptotic death by G93A-SOD1 in primary MNs is
further confirmed using fluorescent TUNEL label-
ing, which results in a dose-dependent increase in
DNA fragmentation [Fig. 4(C)]. Furthermore, com-
parable overexpression of wtSOD1 followed by
TUNEL analysis indicates that there is no apparent
toxicity associated with overexpression of SOD1
itself [Fig. 5(A)].
Axonal degeneration is associated with ALS
pathogenesis (Fischer et al., 2004; Fischer and Glass,
2007); therefore, we next examined MN morphology.
Expression of G93A-SOD1 in primary MNs pro-
motes dose-dependent axonal degeneration repre-
sented by decreased axon length and aberrant branch-
ing [Fig. 4(D–G)], while transfection with AdGFP
does not promote axonal degeneration, again elimi-
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nating any toxic effects due to viral titer alone (data
not shown). These data validate AdmSOD transfec-
tion of primary MNs as a suitable model system for
examining neuroprotection in ALS.
Mechanisms of VEGF Neuroprotection
To examine VEGF neuroprotection in ALS, we treated
primary MNs with 500 or 1000 pfu/MN AdmSOD in
Figure 1 VEGFR expression in G93A-SOD1 and nontransgenic mouse spinal cords. Immuno-
staining for VEGFR1 (A, B), VEGFR2 (C, D), and VEGFR3 (E, F) in nontransgenic (A, C, E) and
G93A-SOD1 (B, D, F) mouse spinal cord sections. Arrows point to VEGFR expression in MNs in
the ventral horn. (G) PCR on RNA isolated from G93A-SOD1 and nontransgenic control mouse
spinal cords for VEGF family ligands and VEGFR RNA. Densitometry followed by one-way
ANOVA and Tukey’s multiple comparison test demonstrates significant decreased expression of
VEGF-A and VEGFR2 RNA in G93A-SOD1 spinal cords compared to nontransgenic control spinal
cords (*p < 0.01). Results are normalized to actin. Scale bar 50 lm. [Color figure can be viewed in the
online issue, which is available at www.interscience.wiley.com.]
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the absence or presence of VEGF and measured DNA
damage using the TUNEL assay [Fig. 5(A)]. VEGF sig-
nificantly decreased the level of DNA damage associ-
ated with G93A-SOD1 expression. To determine the
temporal efficacy of VEGF in AdmSOD-treated MN,
VEGF was administered to MN cultures at the time of
AdmSOD transfection or added 4 h pretransfection or
18 h posttransfection and caspase-3 activation was
examined by Western blotting [Fig. 5(B)]. All VEGF
treatments decrease caspase-3 cleavage associated with
G93A-SOD1, with pretreatment conferring the greatest
efficacy. These data confirm that VEGF is neuroprotec-
tive against G93A-SOD1 caspase-3 cleavage and DNA
damage in primary MNs.
To determine what signaling pathways activated
by VEGF are important in neuroprotection, we uti-
lized pathway-specific inhibitors for PI3K/Akt and
p44/42 MAPK signaling pathways and assessed the
Figure 2 VEGFR expression and activation by VEGF in cultured primary MNs. Immunostaining
of primary MNs for VEGFR2 (B) and the MN marker ChAT (A) demonstrates expression of
VEGFR2 in MNs (C). Treatment with VEGF (250 ng/mL, 30 min) promotes activation of VEGFR2
as indicated by phosphorylation of Y951 (E) and Y1175 (G) throughout the MN cell body and
axon (ChAT positive; arrows) upon VEGF stimulation. Phosphorylation is not seen in the absence
of VEGF treatment (D, F). Scale bar 50 lm.
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ability of VEGF to attenuate G93A-SOD1 DNA dam-
age using the TUNEL assay (see Fig. 6). Inhibition of
the VEGFR2 with SU1498 completely prevented the
neuroprotective effects of VEGF. LY294002, which
prevents signaling via the PI3K/Akt pathway, also
completely prevented VEGF neuroprotection, while
inhibition of p44/42 MAPK signaling using U0126
did not impact the neuroprotective potential of
VEGF. These data indicate that VEGF neuroprotec-
tion against G93A-SOD1 is mediated by activation of
the PI3K/Akt pathway via VEGFR2 activation.
DISCUSSION
To date there are no effective treatments for ALS and
the mechanisms of disease onset and progression
have not been determined. In addition to the toxic
gain-of-function mechanism associated with SOD1
mutations, genetic mutations have also been identi-
fied in Alsin, dynactin, angiogenin, senataxin, and
vesicle-associated membrane protein/synaptobrevin-
associated membrane protein B (Pasinelli and Brown,
2006; Gonzalez de Aguilar et al., 2007; Valdmanis
and Rouleau, 2008). Additional proposed mecha-
nisms of ALS include autoimmune and inflammatory
responses (Appel et al., 1991; Appel et al., 1994),
neurofilament aggregation (Lin et al., 2004; Ge et al.,
2005), mitochondrial impairment (Dupuis et al.,
2004; Bacman et al., 2006; Vande Velde et al., 2008),
oxidative stress (Yim et al., 1996; Liu et al., 2007),
glutamate toxicity (Rothstein et al., 1990; Coyle and
Puttfarcken, 1993), and altered neurotrophism (Ekes-
tern, 2004). The combination of multiple insults and
attenuated protective responses, which are all
reflected in gene profiling data from patients with
ALS (Wang et al., 2006), compounds the neurodege-
nerative phenotype of the MNs. The development of
therapies that can target multiple facets of the disease
will play a crucial role in understanding and treating
ALS. The current study investigates the therapeutic
potential of a neurotrophic factor, VEGF, using the
ALS model system created by expressing G93A-
SOD1 in primary MNs. Expression of G93A-SOD1
in cultured primary MNs induces biochemical and
morphological characteristics of cell death resem-
bling human ALS (see Fig. 4). Overexpression of
wildtype SOD1, on the other hand, does not promote
DNA damage [Fig. 5(A)]. In agreement with this, the
literature strongly supports that only expression of
mutant SOD1 promotes disease (Gurney et al., 1994;
Reaume et al., 1996), confirming that the observed
toxicity is due to expression of mutant SOD1 and not
overexpression of SOD1 itself.
Utilizing cultured E15 rat primary MNs enables us
to examine the effects of VEGF directly on G93A-
SOD1-expressing MNs. While some studies have
examined MNs isolated from transgenic rodent mod-
els of ALS expressing various forms and levels of
mutant SOD1 (Raoul et al., 2002, 2006; Spalloni
et al., 2004; Lobsiger et al., 2007), utilizing rat pri-
mary MNs allows for control over the expression lev-
els and toxicity of G93A-SOD1 (Howland et al.,
2002; Alexander et al., 2004; Goos et al., 2007). This
system results in the morphological and biochemical
alterations associated with ALS MN degeneration
including axonal degeneration, activation of caspase-
3 and DNA damage indicative of cell death (Fig. 4;
Martin, 1999; Li et al., 2000; Fischer et al., 2004;
Fischer and Glass, 2007). The observed severity of
alterations follow a dose-dependant association with
mutant SOD1 expression levels in cultures from both
transgenic animal models expressing different copy
numbers of the mutant SOD1 protein and wildtype
animals transfected with the mutant SOD1 protein
(Howland et al., 2002; Alexander et al., 2004). Taken
Figure 3 VEGF signaling in cultured primary MNs.
Western blotting of primary MNs treated with VEGF. (A)
Time course of Akt and p44/42 MAPK phosphorylation in
response to VEGF (250 ng/mL) treatment. (B) Pretreatment
(1 h) with inhibitors to the PI3K/Akt pathway (LY294002;
20 lM), p44/42 MAPK pathway (U0126; 20 lM), and
VEGFR2 (SU1948; 20 lM) prevents activation of the
respective signaling pathways in response to VEGF
treatment.
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together, while other models exist to study neuropro-
tection in ALS, primary rat MNs provide an ideal
controllable system for the mechanistic studies under-
taken here.
Recently, the role of mutant SOD1 in ALS patho-
genesis has been examined in both MNs and glia. In
agreement with our findings in MN cultures, studies
indicate that expression of G93A-SOD1 exclusively
in MNs is sufficient to promote protein aggregation
and onset of MN degeneration (Jaarsma et al., 2008).
Expression of G93A-SOD1 in glia, however, appears
to play a more important role in disease progression
(Clement et al., 2003; Di Giorgio et al., 2007; Yama-
naka et al., 2008). These focused studies are in agree-
ment with the current understanding of the role of
G93A-SOD1 in MNs and enable us to examine the
contribution and mechanisms of VEGF neuroprotec-
tion at the level of the MN.
Loss of VEGF was first associated with ALS
pathogenesis in 2001 when the deletion of the hy-
poxia response element in the VEGF promoter in
transgenic mice resulted in a phenotype essentially
identical to that of human ALS (Oosthuyse et al.,
2001). Within the G93A-SOD1 mouse spinal cord,
we observe a decrease in VEGF and VEGFR2 levels
concurrent with loss of large MNs (see Fig. 1). This
Figure 4 Effects of G93A-SOD1 on cultured primary MNs. Caspase-3 cleavage in response to
adenoviral transfection of cultured primary MNs with (A) AdmSOD (0–1000 pfu/MN) or (B)
AdGFP (0–1000 pfu/MN). Western blotting demonstrates dose-dependent caspase-3 cleavage
in response to G93A-SOD1 expression in cultured primary MNs, while expression of comparable
amounts of GFP do not, ruling out toxic effects of viral titer alone. (C) Fluorescent TUNEL staining
of AdmSOD-transfected primary MNs. Results are averaged from three independent experiments and
analyzed for statistical significance using one-way ANOVA followed by Tukey’s multiple compari-
son test (*p < 0.01). (D–G) Immunostaining of MNs transfected with AdmSOD for the MN marker
ChAT demonstrates dose-dependent effects of G93A-SOD1 on MN morphology. [Color figure can
be viewed in the online issue, which is available at www.interscience.wiley.com.]
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decrease in VEGF and VEGFR2 expression is not
associated with a compensatory upregulation of other
VEGF family members [Fig. 1(G)]. Reductions in
VEGF and VEGFR2 are also evident in patients with
ALS (Brockington et al., 2006), and the role of
VEGF in ALS is further supported by evidence
that mutant SOD1 destabilizes VEGF mRNA (Lu et
al., 2007). Reduced VEGFR2 levels can potentially
result in decreased responsiveness to VEGF neurotro-
phism, or reduced VEGF may increase MN suscepti-
bility to additional cellular insults promoting disease
progression.
For VEGF treatment to be efficacious in ALS,
remaining MNs in the spinal cord must be capable of
responding to VEGF. Immunostaining for VEGFRs
in G93A-SOD1 mouse spinal cords demonstrates that
the remaining MNs express all three VEGFRs [Fig.
1(B,D,F)], and expression of VEGFR2 is also demon-
strated in cultured primary MNs [Fig. 2(A–C)]. Fur-
thermore, cultured primary MNs respond to VEGF
treatment, as evidenced by phosphorylation and acti-
vation of VEGFR2 [Fig. 2(D–G)]. These data confirm
that MNs in the spinal cord and in our culture system
are capable of responding to exogenous VEGF appli-
cation.
The current studies demonstrate that VEGF can
protect MNs from G93A-SOD1-induced damage.
Addition of VEGF significantly prevents G93A-
SOD1-induced DNA fragmentation [Fig. 5(A)] and
caspase-3 cleavage [Fig. 5(B)]. While VEGF pro-
vides lower levels of neuroprotection when adminis-
tered concurrent with or following G93A-SOD1
transfection compared to pretreatment, the ability to
Figure 5 VEGF neuroprotection against G93A-SOD1 in
cultured primary MNs. (A) TUNEL labeling demonstrates
increased DNA damage associated with 500 and 1000 pfu/
MN AdmSOD transfection, which is significantly attenu-
ated in the presence of VEGF (250 ng/mL). Transfection
with equal concentrations of AdwtSOD1 does not result in
increased DNA damage. MN densities are equivalent
between treatments groups, and results are averaged over at
least 10 fields of three independent experiments and ana-
lyzed for statistical significance using one-way ANOVA
followed by Tukey’s multiple comparison test (*p < 0.05).
(B) Western blotting demonstrates decreased levels of
G93A-SOD1-induced caspase-3 cleavage with VEGF treat-
ment. Pretreatment (4 h pre) is the most efficacious, with
decreased efficacy associated with VEGF cotreatment or
posttreatment (18 h post).
Figure 6 Identification of VEGF signaling pathways
involved in neuroprotection against G93A-SOD1. TUNEL
labeling to identify signaling pathways responsible for
VEGF neuroprotection against G93A-SOD1-induced DNA
fragmentation. Treatment with AdmSOD (1000 ng/mL)
results in DNA damage and is significantly attenuated by
VEGF treatment (250 ng/mL). Inhibition of VEGFR2 sig-
naling with SU1498 (20 lM; 1 h pretreatment) prevents
VEGF neuroprotection. Inhibition of PI3K/Akt signaling
with LY294002 (20 lM; 1 h pretreatment) also prevents
VEGF neuroprotection, while inhibition of p44/42 MAPK
signaling with U0126 (20 lM; 1 h pretreatment) has no
effect on VEGF neuroprotection. Results are averaged over
at least 10 fields of three independent experiments and ana-
lyzed for statistical significance using one-way ANOVA
followed by Tukey’s multiple comparison test (*p < 0.01
compared to mSOD + VEGF).
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decrease caspase-3 cleavage in this in vitro system
that represents an endstage disease phenotype implies
that VEGF treatment efficacy, when translated into
the human MN environment, could be effective
throughout the disease course. These findings are
congruent with previous reports supporting the neuro-
protective effects of VEGF in ALS. Retrograde deliv-
ery of VEGF to MNs by gene therapy increases sur-
vival of G93A-SOD1 transgenic mice (Azzouz et al.,
2004). Systemic delivery of VEGF also decreases
astrogliosis and increases neuromuscular junctions in
these mice (Zheng et al., 2007). Double transgenic
mice expressing G93A-SOD1 and increased VEGF
levels demonstrate delayed MN loss, delayed motor
impairment, and increased survival (Wang et al.,
2007). G93A-SOD1 transgenic rats also show evi-
dence of increased survival in response to treatment
with intracerebroventricular delivery of VEGF (Stor-
kebaum et al., 2005). G93A-SOD1 expression in a
zebrafish model of ALS also demonstrates attenua-
tion of G93A-SOD1-induced neuronal defects with
increased VEGF levels and exacerbated defects with
decreased VEGF concentrations (Lemmens et al.,
2007).
Our findings demonstrate that VEGF is neuro-
protective against G93A-SOD1 toxicity (see Fig.
5). This data suggests that the decreased toxicity
and increased MN survival in response to VEGF
treatment, which is supported in additional reports
(Li et al., 2003; Zheng et al., 2004, 2007; Dewil
et al., 2007), may indicate a role for VEGF neuro-
protection in ALS. In fact, VEGF is protective
against glutamate toxicity in spinal cord cultures,
one of the main non-neuronal mechanisms of MN
damage in ALS (Tovar et al., 2007; Tolosa et al.,
2008). These data, along with the finding of
reduced VEGF levels in transgenic ALS mouse spi-
nal cords [Fig. 1(G)], suggest that the loss of
VEGF neurotrophism may be a contributing factor
to MN survival in ALS. Restoration of VEGF lev-
els, therefore, is supported as a viable approach to
treating MN degeneration in ALS.
VEGF activates many signaling pathways in
MNs including PI3K/Akt and p44/42 MAPK (see
Fig. 3). We have previously demonstrated that
PI3K/Akt and p44/42 MAPK signaling are involved
in the neuroprotective effects of insulin-like growth
factor-I (IGF-I) against glutamate toxicity (Vincent
et al., 2004). We are able to address the contribu-
tion of these signaling pathways to VEGF neuro-
protection in our model system using the pathway-
specific inhibitors LY294002 and U0126 to prevent
PI3K/Akt and p44/42 MAPK signaling, respectively
(Vlahos et al., 1994; Favata et al., 1998). Work in
our laboratory and others (Kim et al., 1998; Lein-
ninger et al., 2004; Vincent et al., 2004, 2007)
have extensively examined and optimized these
inhibitors for dosing regimens and their selective
effectiveness in neuronal cultures, and at the con-
centrations used for these studies, inhibitor concen-
trations are sufficient to prevent activation of the
respective pathways [Fig. 3(B)] with minimal toxic-
ity. Unlike results from studies examining IGF-I
neuroprotection (Vincent et al., 2004), our results
demonstrate that VEGF-induced PI3K/Akt signaling
is neuroprotective against G93A-SOD1 toxicity,
with no apparent involvement of p44/42 MAPK
signaling (see Fig. 6). The role of PI3K/Akt in
ALS has been previously examined in various sys-
tems with conflicting results. Familial and sporadic
ALS patients have decreased levels of phosphoryl-
ated Akt in MNs, as also evidenced in G93A-
SOD1 mice prior to symptom onset (Dewil et al.,
2007). Examination of phosphorylated Akt levels in
G93A-SOD1 mouse spinal cords in an alternate
study, however, demonstrated no change in phos-
phorylated Akt (Peviani et al., 2007). Despite these
discrepancies, constitutive activation of Akt in
G37R-SOD1-expressing N2a cells provides neuro-
protection (Dewil et al., 2007). Furthermore, neuro-
protective effects of intracerebroventricular VEGF
treatment in G93A-SOD1 rats result in increased
phospho-Akt levels (Dewil et al., 2007). Therefore,
VEGF specifically mediates its protective effects
via PI3K/Akt signaling, which may constitute a
conserved mechanism for VEGF neuroprotection in
ALS.
VEGF efficacy has also been previously examined
in models of sporadic ALS. Familial ALS and spo-
radic ALS are clinically and pathologically indistin-
guishable, and it is suggested that both forms of the
disease potentially result from a common mechanism.
Reports on sporadic ALS demonstrate an involve-
ment of non-neuronal glutamate toxicity in MN
degeneration and disease progression (Rothstein
et al., 1990; Coyle and Puttfarcken, 1993; Clement
et al., 2003; Boillee et al., 2006; Di Giorgio et al.,
2007; Yamanaka et al., 2008). In fact, VEGF
decreases MN loss by over 75% in a rat model of
excitotoxic MN degeneration (Tovar et al., 2007).
Activation of PI3K/Akt signaling by IGF-I is also
associated with neuroprotection against glutamate
toxicity (Vincent et al., 2004). Tolosa et al. (2008)
demonstrated direct neuroprotection by VEGF via
PI3K/Akt signaling against excitotoxic stress.
Taken together, the current studies strengthen
the role of VEGF as a therapy for ALS. We have
established that VEGF-mediated PI3K/Akt signaling
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is an important mechanism for protection against
G93A-SOD1 in MNs. Induction of PI3K/Akt sig-
naling by VEGF may constitute a conserved neuro-
protective mechanism for MNs in response to a
number of cellular insults in ALS pathogenesis
including mutant SOD1 and glutamate toxicity.
These data support the idea that G93A-SOD1 pro-
motes destabilization of VEGF mRNA and
decreased protein levels. The reduced protein level
propagates susceptibility onto the MNs to addi-
tional cellular insults, contributing to disease onset.
MNs remaining in the ALS spinal cord, however,
are capable of responding to VEGF stimulation and
thus can respond to therapeutic exogenous VEGF
administration via activation of PI3K/Akt signaling
resulting in neuroprotection (see Fig. 7).
Determining the most efficacious delivery mech-
anism for VEGF is important for achieving neuro-
protection in ALS, and gene-based therapies offer
much potential for effective delivery of therapeutics
to MNs (Federici and Boulis, 2006). Achieving the
maximal impact of VEGF neurotrophism is also im-
portant to consider. The current studies investigate
the efficacy of VEGF165, one of the five VEGF
splice variants normally expressed in the nervous
system. Induction of the full biological array of
VEGF isoforms, however, may promote an additive
effect on neuroprotection (Whitlock et al., 2004;
Amano et al., 2005) and increased potency and lon-
gevity of VEGF neuroprotection may be observed.
Studies are currently underway to establish a more
efficacious delivery mechanism using gene-based
treatment strategies to increase PI3K/Akt activation
in ALS using the full biological array of VEGF
splice variants.
The authors would also like to thank Ms. Judith Boldt
for excellent secretarial support during the preparation of
this manuscript.
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